Effect of oral contraceptives on vascular endothelial growth factor, Cox-2 and aromatase expression in the endometrium of uteri affected by myomas and associated pathologies

Hugo Maia, Julio Casoy, Júlio Casoy, Kleber Pimentel, Tania Correia, Tânia Correia, Célia Athayde, Thomaz Cruz, Elsimar Metzker Coutinho
Contraception · 2008 · vol. 78(6) , pp. 479–485 · doi:10.1016/j.contraception.2008.07.002 · PMID:19014794 · W2082270477
article OA: green CC0 ⤵ 11 in-corpus citations
🔓 Open OA copy Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06+body, 2026-06-08 ⓘ

This study evaluated VEGF, Cox-2, and aromatase expression in the endometrium of women with myomas and menorrhagia, finding their expression was greater in the proliferative phase than the luteal phase or after oral contraceptive use.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 · read from full text ⓘ

This study evaluated vascular endothelial growth factor (VEGF), Cox-2, and aromatase expression in the endometrium of 118 reproductive-age women with uterine myomas and menorrhagia, including 40 users of an oral contraceptive pill containing gestodene and ethinylestradiol. Using hysteroscopy and immunohistochemistry, the authors found that aromatase, Cox-2, and VEGF expression were higher in the proliferative phase than in the luteal phase and were reduced following oral contraceptive use; the paper concludes that endogenous progesterone or combined oral contraceptives inhibit these markers in this endometrial context. A stated limitation is that the results rely on immunohistochemical expression measurements rather than direct functional outcomes. Relevance to endometriosis: endometriosis was reported as an associated pathology in 17% of cases, though the paper’s main focus is marker expression effects of oral contraceptives in myoma-associated menorrhagia.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 2,414 characters · extracted from oa-html · click to expand
Please use this identifier to cite or link to this item: https://repositorio.ufba.br/handle/ri/5949 | metadata.dc.type: | Artigo de Periódico | | Title: | Effect of oral contraceptives on vascular endothelial growth factor, Cox-2 and aromatase expression in the endometrium of uteri affected by myomas and associated pathologies | | Other Titles: | Contraception | | Authors: | Maia Junior, Hugo Casoy, Julio Pimentel, Kleber Santos Correia, Tania Athayde, Célia Maria Soares Cruz, Thomaz Rodrigues Porto da Coutinho, Elsimar Metzker | | metadata.dc.creator: | Maia Junior, Hugo Casoy, Julio Pimentel, Kleber Santos Correia, Tania Athayde, Célia Maria Soares Cruz, Thomaz Rodrigues Porto da Coutinho, Elsimar Metzker | | Abstract: | Background: The study was conducted to evaluate vascular endothelial growth factor (VEGF), Cox-2 and aromatase expression in the endometrium of uteri with myomas and other associated pathologies. Study Design: Hysteroscopy was performed in 118 women of reproductive age with myomas and menorrhagia, 40 of whom were using a pill containing 75 mcg gestodene+30 mcg ethinylestradiol. Aromatase p450, VEGF and Cox-2 expression was detected using immunohistochemistry. Fisher's Exact Test and the Mann–Whitney test were used in the statistical analysis, with significance established at pb.05. Results: In patients with myomas and menorrhagia, associated pathologies such as adenomyosis, endometrial polyps and endometriosis were found in 32%, 12% and 17% of cases, respectively. Aromatase, Cox-2 and VEGF expression was greater during the proliferative phase compared to the luteal phase of the cycle or following oral contraceptive use. Conclusion: Endogenous progesterone or combined oral contraceptives are potent inhibitors of VEGF, aromatase and Cox-2 expression in the endometrium of patients with myomas and menorrhagia. © 2008 Elsevier Inc. All rights reserved. | | Keywords: | Gestodene VEGF Aromatase Cox-2 Myoma Menorrhagia | | URI: | http://www.repositorio.ufba.br/ri/handle/ri/5949 | | Issue Date: | 2008 | | Appears in Collections: | Artigo Publicado em Periódico (Faculdade de Medicina) | Files in This Item: | File | Description | Size | Format | | |---|---|---|---|---| | __ac.els-cdn.com_S001078...0301810acfa88fb02630e508e51d6.pdf | 283,44 kB | Adobe PDF | View/Open | Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

MeSH descriptors

Contraceptives, Oral Endometrium Endometrium Menorrhagia Uterine Neoplasms Adult Aromatase Aromatase Contraceptives, Oral Cyclooxygenase 2 Cyclooxygenase 2 Endometrium Endometrium Female Humans Hysterectomy Immunohistochemistry Luteal Phase Menorrhagia Menorrhagia

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (33)

Cited by (11)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:14:24.299271+00:00
License: CC0 · commercial use OK